Literature DB >> 9525643

B-lymphocyte proliferation during bovine leukemia virus-induced persistent lymphocytosis is enhanced by T-lymphocyte-derived interleukin-2.

E S Trueblood1, W C Brown, G H Palmer, W C Davis, D M Stone, T F McElwain.   

Abstract

Bovine leukemia virus (BLV)-induced persistent lymphocytosis is characterized by a polyclonal expansion of CD5+ B lymphocytes. To examine the role of the cytokine microenvironment in this virus-induced B-lymphocyte expansion, the expression of interleukin-2 (IL-2), IL-4, IL-10, and gamma interferon (IFN-gamma) mRNA, was measured in stimulated peripheral blood mononuclear cells from persistently lymphocytotic BLV-infected cows, nonlymphocytotic BLV-infected cows, and uninfected cows. IL-2 and IL-10 mRNA expression and IL-2 functional activity were significantly increased when peripheral blood mononuclear cells from persistently lymphocytotic cows were stimulated with concanavalin A (ConA). Additionally, during persistent lymphocytosis, peak IL-2 and IL-10 mRNA expression was delayed, and elevated expression was prolonged. To determine the potential biologic importance of increased IL-2 and IL-10 expression, the response of isolated B lymphocytes from persistently lymphocytotic cows to human recombinant cytokines and to cytokine-containing supernatants from isolated T lymphocytes was examined. While recombinant human IL-10 (rhIL-10) did not consistently induce detectable changes, rhIL-2 increased viral protein (p24) and IL-2 receptor expression in isolated B lymphocytes from persistently lymphocytotic cows. Additionally, rhIL-2 and supernatant from ConA-stimulated T lymphocytes enhanced B-lymphocyte proliferation. The stimulatory activity of the T-lymphocyte supernatant could be completely inhibited with a polyclonal anti-rhIL-2 antibody. Finally, polyclonal anti-rhIL-2 antibody, as well as anti-BLV antibody, inhibited spontaneous proliferation of peripheral blood mononuclear cells from persistently lymphocytotic cows, demonstrating that the spontaneous lymphoproliferation characteristic of BLV-induced persistent lymphocytosis is IL-2 dependent and antigen dependent. Collectively, these findings strongly suggest that increased T-lymphocyte expression of IL-2 in BLV-infected cows contributes to development and/or maintenance of persistent B lymphocytosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525643      PMCID: PMC109775     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

Review 1.  Diseases associated with HTLV-I: virus, IL-2 receptor dysregulation and redox regulation.

Authors:  J Yodoi; T Uchiyama
Journal:  Immunol Today       Date:  1992-10

Review 2.  Human T cell leukemia virus type I (HTLV-I) and human diseases.

Authors:  T Uchiyama
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

3.  Polymorphism in BoLA-DRB3 exon 2 correlates with resistance to persistent lymphocytosis caused by bovine leukemia virus.

Authors:  A Xu; M J van Eijk; C Park; H A Lewin
Journal:  J Immunol       Date:  1993-12-15       Impact factor: 5.422

Review 4.  Interleukin-10.

Authors:  K W Moore; A O'Garra; R de Waal Malefyt; P Vieira; T R Mosmann
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

5.  Enhanced B-lymphocyte expression of IL-2R alpha associated with T lymphocytosis in BLV-infected persistently lymphocytotic cows.

Authors:  D M Stone; T F McElwain; W C Davis
Journal:  Leukemia       Date:  1994-06       Impact factor: 11.528

6.  Inhibition of protein kinase C results in decreased expression of bovine leukemia virus.

Authors:  W A Jensen; B J Wicks-Beard; G L Cockerell
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

7.  IFN-gamma stimulates IgG2 production from bovine B cells costimulated with anti-mu and mitogen.

Authors:  D M Estes; N M Closser; G K Allen
Journal:  Cell Immunol       Date:  1994-04-01       Impact factor: 4.868

8.  Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus.

Authors:  M Clerici; T A Wynn; J A Berzofsky; S P Blatt; C W Hendrix; A Sher; R L Coffman; G M Shearer
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

9.  Characterization of a cDNA encoding bovine interleukin 10: kinetics of expression in bovine lymphocytes.

Authors:  S M Hash; W C Brown; A C Rice-Ficht
Journal:  Gene       Date:  1994-02-25       Impact factor: 3.688

10.  Interleukin 10 (IL-10) upregulates functional high affinity IL-2 receptors on normal and leukemic B lymphocytes.

Authors:  A C Fluckiger; P Garrone; I Durand; J P Galizzi; J Banchereau
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

View more
  12 in total

1.  Intestinal Shiga toxin-producing Escherichia coli bacteria mitigate bovine leukemia virus infection in experimentally infected sheep.

Authors:  Witold A Ferens; Rowland Cobbold; Carolyn J Hovde
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Bovine CD4(+) T-lymphocyte clones specific for rhoptry-associated protein 1 of Babesia bigemina stimulate enhanced immunoglobulin G1 (IgG1) and IgG2 synthesis.

Authors:  W C Brown; T F McElwain; G H Palmer; S E Chantler; D M Estes
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

3.  Purified bovine plasma blocking factor decreases Bovine leukemia virus p24 expression while increasing protein synthesis and transcriptional activity of peripheral blood mononuclear cells in short-term culture.

Authors:  Marianne J van den Heuvel; Barbara J Jefferson; Robert M Jacobs
Journal:  Can J Vet Res       Date:  2005-07       Impact factor: 1.310

4.  CD5 is dissociated from the B-cell receptor in B cells from bovine leukemia virus-infected, persistently lymphocytotic cattle: consequences to B-cell receptor-mediated apoptosis.

Authors:  G H Cantor; S M Pritchard; F Dequiedt; L Willems; R Kettmann; W C Davis
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  Antiviral activity of shiga toxin 1: suppression of bovine leukemia virus-related spontaneous lymphocyte proliferation.

Authors:  W A Ferens; C J Hovde
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

6.  Relationship of persistent lymphocytosis, antibody titers, and proviral load with expression of interleukin-12, interferon-γ, interleukin-2, interleukin-4, interleukin-10, and transforming growth factor-β in cows infected with bovine leukemia virus from a high-prevalence dairy complex.

Authors:  Ernesto Marin-Flamand; Diana Michele Araiza-Hernandez; Alejandro Vargas-Ruiz; Ignacio Carlos Rangel-Rodríguez; Lilia A González-Tapia; Hugo Ramírez-Álvarez; Ruperto Javier Hernández-Balderas; Lucía Angélica García-Camacho
Journal:  Can J Vet Res       Date:  2022-10       Impact factor: 0.897

7.  Bovine leukemia virus-induced persistent lymphocytosis in cattle does not correlate with increased ex vivo survival of B lymphocytes.

Authors:  F Dequiedt; G H Cantor; V T Hamilton; S M Pritchard; W C Davis; P Kerkhofs; A Burny; R Kettmann; L Willems
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  DNA and a CpG oligonucleotide derived from Babesia bovis are mitogenic for bovine B cells.

Authors:  W C Brown; D M Estes; S E Chantler; K A Kegerreis; C E Suarez
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

9.  Reduced cell turnover in bovine leukemia virus-infected, persistently lymphocytotic cattle.

Authors:  Christophe Debacq; Becca Asquith; Michal Reichert; Arsène Burny; Richard Kettmann; Luc Willems
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Milk Macrophage Function in Bovine Leukemia Virus-Infected Dairy Cows.

Authors:  Ewerton de Souza Lima; Maiara Garcia Blagitz; Camila Freitas Batista; Alexandre José Alves; Artur Cezar de Carvalho Fernandes; Eduardo Milton Ramos Sanchez; Hugo Frias Torres; Soraia Araújo Diniz; Marcos Xavier Silva; Alice Maria Melville Paiva Della Libera; Fernando Nogueira de Souza
Journal:  Front Vet Sci       Date:  2021-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.